{"id":5404,"date":"2022-07-04T01:07:33","date_gmt":"2022-07-04T01:07:33","guid":{"rendered":"\/\/smallcapscn.x5view.co\/?p=5404"},"modified":"2023-08-29T18:01:33","modified_gmt":"2023-08-29T18:01:33","slug":"invex-therapeutics-approved-start-presendin-phase-three-clinical-trial-australia","status":"publish","type":"post","link":"https:\/\/smallcapscn.x5view.co\/?p=5404","title":{"rendered":"Invex Therapeutics \u83b7\u51c6\u5728\u6fb3\u5927\u5229\u4e9a\u542f\u52a8 Presendin \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c"},"content":{"rendered":"

\u4e34\u5e8a\u9636\u6bb5\u7684\u751f\u7269\u5236\u836f\u516c\u53f8 Invex Therapeutics (ASX: IXC) \u5df2\u83b7\u51c6\u5728\u6fb3\u5927\u5229\u4e9a\u5f00\u59cb\u5176\u9488\u5bf9\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u7684 EVOLVE \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002<\/p>\n

\u8be5\u516c\u53f8\u4eca\u5929\u5ba3\u5e03\uff0c\u5b83\u5df2\u83b7\u5f97\u4eba\u7c7b\u7814\u7a76\u4f26\u7406\u59d4\u5458\u4f1a (Human Research Ethics Committee\uff1bHREC) \u7684\u6279\u51c6\u4ee5\u53ca\u6fb3\u5927\u5229\u4e9a\u6cbb\u7597\u7528\u54c1\u7ba1\u7406\u5c40 (Australia\u2019s Therapeutics Goods Administration\uff1bTGA) \u7684\u4e34\u5e8a\u8bd5\u9a8c\u901a\u77e5 (Clinical Trial Notification\uff1bCTN) \u8ba1\u5212\u6279\u51c6\u3002<\/p>\n

\u8be5\u8bd5\u9a8c\u65e8\u5728\u8bc4\u4f30 Invex \u7684\u4e3b\u8981\u836f\u7269 Presendin \u5bf9\u65b0\u8bca\u65ad\u7684 IIH \u60a3\u8005\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u3002 HREC \u6279\u51c6\u6db5\u76d6\u4e86\u6fb3\u5927\u5229\u4e9a\u7684\u4e00\u4e9b\u79c1\u7acb\u533b\u9662\uff0cInvex \u8fd8\u5e0c\u671b\u4e3a\u4e00\u5bb6\u516c\u7acb\u533b\u9662\u63d0\u4ea4\u989d\u5916\u7684\u5355\u72ec HREC \u7533\u8bf7\u3002<\/p>\n

\u8be5\u516c\u53f8\u5c1a\u672a\u63d0\u4f9b\u5f00\u59cb\u65e5\u671f\uff0c\u4f46\u786e\u8ba4\u201c\u4e00\u65e6\u5b8c\u6210\u5355\u72ec\u7684\u673a\u6784\u6388\u6743\u201d\uff0c\u5b83\u4ecd\u6709\u671b\u5f00\u59cb\u62db\u52df\u60a3\u8005\u3002<\/p>\n

Invex \u6267\u884c\u8463\u4e8b\u517c\u9996\u5e2d\u79d1\u5b66\u5b98 Alex Sinclair \u6559\u6388\u8868\u793a\uff0c\u516c\u53f8\u5f88\u9ad8\u5174\u83b7\u51c6\u5f00\u59cb\u8fd9\u9879\u7814\u7a76\u3002<\/p>\n

Sinclair \u6559\u6388\u8bf4\uff1a\u201c\u6211\u4eec\u8ba4\u4e3a\uff0cIIH \u7f3a\u4e4f\u83b7\u6279\u7684\u6cbb\u7597\u65b9\u6cd5\u4ee5\u53ca\u8be5\u7814\u7a76\u4eba\u7fa4\u4e2d\u76f8\u5173\u672a\u6ee1\u8db3\u7684\u533b\u7597\u9700\u6c42\uff0c\u8fd9\u5bf9\u4e8e\u5f3a\u5927\u7684\u4e34\u5e8a\u533b\u751f\u652f\u6301\u3001\u6709\u6548\u7684\u60a3\u8005\u5165\u7ec4\u548c\u6267\u884c\u8fd9\u9879\u9ad8\u8d28\u91cf\u7684\u968f\u673a\u5bf9\u7167\u4e34\u5e8a\u8bd5\u9a8c\u6765\u8bf4\u662f\u4e00\u4e2a\u5f88\u597d\u7684\u7ed3\u679c\u3002\u201d<\/p>\n

IIH EVOLVE \u4e09\u671f\u8bd5\u9a8c<\/h2>\n

IIH EVOLVE \u662f\u4e00\u9879\u968f\u673a\u3001\u5b89\u6170\u5242\u5bf9\u7167\u3001\u53cc\u76f2\u8bd5\u9a8c\uff0c\u65e8\u5728\u786e\u5b9a Invex \u7684\u4e3b\u8981\u836f\u7269 Presendin \u7684\u7597\u6548\u548c\u5b89\u5168\u6027\uff0cPresendin \u662f\u4e00\u79cd\u76ae\u4e0b\u3001\u6301\u7eed\u91ca\u653e\u7684 Exanatide \u5fae\u7403\u5236\u5242\u3002<\/p>\n

\u8be5\u8bd5\u9a8c\u5c06\u6d89\u53ca 240 \u540d\u65b0\u8bca\u65ad\u7684 IIH \u60a3\u8005\uff0c\u6bcf\u5468\u4e00\u6b21\u670d\u7528 Presendin \u6216\u5b89\u6170\u5242\uff0c\u6301\u7eed 24 \u5468\u3002<\/p>\n

\u8be5\u8bd5\u9a8c\u7684\u4e3b\u8981\u7ec8\u70b9\u662f\u9885\u5185\u538b\u76f8\u5bf9\u4e8e\u57fa\u7ebf\u7684\u53d8\u5316\uff0c\u5173\u952e\u7684\u6b21\u8981\u7ec8\u70b9\u4e0e\u89c6\u529b\u548c\u5934\u75db\u7ed3\u679c\u6d4b\u91cf\u6709\u5173\u3002<\/p>\n

Invex \u8ba1\u5212\u5728\u5168\u7403\u5f00\u8bbe\u591a\u8fbe 40 \u4e2a\u4e34\u5e8a\u7ad9\u70b9\u3002\u4e0a\u5468\uff0c\u8be5\u516c\u53f8\u5ba3\u5e03\u5df2\u83b7\u5f97\u5728\u82f1\u56fd\u8fdb\u884c\u8bd5\u9a8c\u7684\u76d1\u7ba1\u6279\u51c6<\/a>\uff0c\u9884\u8ba1\u5c06\u4e8e 6 \u6708 30 \u65e5\u4e4b\u540e\u5f00\u59cb\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"

\u4e34\u5e8a\u9636\u6bb5\u7684\u751f\u7269\u5236\u836f\u516c\u53f8 Invex Therapeutics (ASX: IXC) \u5df2\u83b7\u51c6\u5728\u6fb3\u5927\u5229\u4e9a\u5f00\u59cb\u5176\u9488\u5bf9\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u7684 EVOLVE \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002 \u8be5\u516c\u53f8\u4eca\u5929\u5ba3\u5e03\uff0c\u5b83\u5df2\u83b7\u5f97\u4eba\u7c7b\u7814\u7a76\u4f26\u7406\u59d4\u5458\u4f1a (Human Research Ethics Committee\uff1bHREC) \u7684\u6279\u51c6\u4ee5\u53ca\u6fb3\u5927\u5229\u4e9a\u6cbb\u7597\u7528\u54c1\u7ba1\u7406\u5c40 (Australia\u2019s Therapeutics Goods Administration\uff1bTGA) \u7684\u4e34\u5e8a\u8bd5\u9a8c\u901a\u77e5 (Clinical Trial Notification\uff1bCTN) \u8ba1\u5212\u6279\u51c6\u3002 \u8be5\u8bd5\u9a8c\u65e8\u5728\u8bc4\u4f30 Invex \u7684\u4e3b\u8981\u836f\u7269 Presendin \u5bf9\u65b0\u8bca\u65ad\u7684 IIH \u60a3\u8005\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u3002 HREC \u6279\u51c6\u6db5\u76d6\u4e86\u6fb3\u5927\u5229\u4e9a\u7684\u4e00\u4e9b\u79c1\u7acb\u533b\u9662\uff0cInvex \u8fd8\u5e0c\u671b\u4e3a\u4e00\u5bb6\u516c\u7acb\u533b\u9662\u63d0\u4ea4\u989d\u5916\u7684\u5355\u72ec HREC \u7533\u8bf7\u3002 \u8be5\u516c\u53f8\u5c1a\u672a\u63d0\u4f9b\u5f00\u59cb\u65e5\u671f\uff0c\u4f46\u786e\u8ba4\u201c\u4e00\u65e6\u5b8c\u6210\u5355\u72ec\u7684\u673a\u6784\u6388\u6743\u201d\uff0c\u5b83\u4ecd\u6709\u671b\u5f00\u59cb\u62db\u52df\u60a3\u8005\u3002 Invex \u6267\u884c\u8463\u4e8b\u517c\u9996\u5e2d\u79d1\u5b66\u5b98 Alex Sinclair \u6559\u6388\u8868\u793a\uff0c\u516c\u53f8\u5f88\u9ad8\u5174\u83b7\u51c6\u5f00\u59cb\u8fd9\u9879\u7814\u7a76\u3002 Sinclair \u6559\u6388\u8bf4\uff1a\u201c\u6211\u4eec\u8ba4\u4e3a\uff0cIIH \u7f3a\u4e4f\u83b7\u6279\u7684\u6cbb\u7597\u65b9\u6cd5\u4ee5\u53ca\u8be5\u7814\u7a76\u4eba\u7fa4\u4e2d\u76f8\u5173\u672a\u6ee1\u8db3\u7684\u533b\u7597\u9700\u6c42\uff0c\u8fd9\u5bf9\u4e8e\u5f3a\u5927\u7684\u4e34\u5e8a\u533b\u751f\u652f\u6301\u3001\u6709\u6548\u7684\u60a3\u8005\u5165\u7ec4\u548c\u6267\u884c\u8fd9\u9879\u9ad8\u8d28\u91cf\u7684\u968f\u673a\u5bf9\u7167\u4e34\u5e8a\u8bd5\u9a8c\u6765\u8bf4\u662f\u4e00\u4e2a\u5f88\u597d\u7684\u7ed3\u679c\u3002\u201d IIH EVOLVE \u4e09\u671f\u8bd5\u9a8c IIH EVOLVE \u662f\u4e00\u9879\u968f\u673a\u3001\u5b89\u6170\u5242\u5bf9\u7167\u3001\u53cc\u76f2\u8bd5\u9a8c\uff0c\u65e8\u5728\u786e\u5b9a Invex \u7684\u4e3b\u8981\u836f\u7269 Presendin… Continue reading Invex Therapeutics \u83b7\u51c6\u5728\u6fb3\u5927\u5229\u4e9a\u542f\u52a8 Presendin \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c<\/span><\/a><\/p>\n","protected":false},"author":5,"featured_media":18675,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[273],"yoast_head":"\nInvex Therapeutics \u83b7\u51c6\u5728\u6fb3\u5927\u5229\u4e9a\u542f\u52a8 Presendin \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c<\/title>\n<meta name=\"description\" content=\"\u4e34\u5e8a\u9636\u6bb5\u7684\u751f\u7269\u5236\u836f\u516c\u53f8 Invex Therapeutics (ASX: IXC) \u5df2\u83b7\u51c6\u5728\u6fb3\u5927\u5229\u4e9a\u5f00\u59cb\u5176\u9488\u5bf9\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u7684 EVOLVE \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Invex Therapeutics \u83b7\u51c6\u5728\u6fb3\u5927\u5229\u4e9a\u542f\u52a8 Presendin \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\" \/>\n<meta property=\"og:description\" content=\"\u4e34\u5e8a\u9636\u6bb5\u7684\u751f\u7269\u5236\u836f\u516c\u53f8 Invex Therapeutics (ASX: IXC) \u5df2\u83b7\u51c6\u5728\u6fb3\u5927\u5229\u4e9a\u5f00\u59cb\u5176\u9488\u5bf9\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u7684 EVOLVE \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-approved-start-presendin-phase-three-clinical-trial-australia\/\" \/>\n<meta property=\"og:site_name\" content=\"smallcapsCN\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-04T01:07:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-29T18:01:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/IND8471.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Small Caps\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Small Caps\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-approved-start-presendin-phase-three-clinical-trial-australia\/\",\"url\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-approved-start-presendin-phase-three-clinical-trial-australia\/\",\"name\":\"Invex Therapeutics \u83b7\u51c6\u5728\u6fb3\u5927\u5229\u4e9a\u542f\u52a8 Presendin \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\",\"isPartOf\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\"},\"datePublished\":\"2022-07-04T01:07:33+00:00\",\"dateModified\":\"2023-08-29T18:01:33+00:00\",\"author\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74\"},\"description\":\"\u4e34\u5e8a\u9636\u6bb5\u7684\u751f\u7269\u5236\u836f\u516c\u53f8 Invex Therapeutics (ASX: IXC) \u5df2\u83b7\u51c6\u5728\u6fb3\u5927\u5229\u4e9a\u5f00\u59cb\u5176\u9488\u5bf9\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u7684 EVOLVE \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002\",\"breadcrumb\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-approved-start-presendin-phase-three-clinical-trial-australia\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-approved-start-presendin-phase-three-clinical-trial-australia\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-approved-start-presendin-phase-three-clinical-trial-australia\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/smallcapscn.x5view.co\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Invex Therapeutics \u83b7\u51c6\u5728\u6fb3\u5927\u5229\u4e9a\u542f\u52a8 Presendin \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\",\"url\":\"https:\/\/smallcapscn.x5view.co\/\",\"name\":\"smallcapsCN\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74\",\"name\":\"Small Caps\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g\",\"caption\":\"Small Caps\"},\"description\":\"Small Caps provides coverage on Australian ASX listed small cap stocks across all sectors: mining, resources, energy, biotech, technology, juniors and IPOs.\",\"url\":\"https:\/\/smallcapscn.x5view.co\/?author=5\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Invex Therapeutics \u83b7\u51c6\u5728\u6fb3\u5927\u5229\u4e9a\u542f\u52a8 Presendin \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c","description":"\u4e34\u5e8a\u9636\u6bb5\u7684\u751f\u7269\u5236\u836f\u516c\u53f8 Invex Therapeutics (ASX: IXC) \u5df2\u83b7\u51c6\u5728\u6fb3\u5927\u5229\u4e9a\u5f00\u59cb\u5176\u9488\u5bf9\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u7684 EVOLVE \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Invex Therapeutics \u83b7\u51c6\u5728\u6fb3\u5927\u5229\u4e9a\u542f\u52a8 Presendin \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c","og_description":"\u4e34\u5e8a\u9636\u6bb5\u7684\u751f\u7269\u5236\u836f\u516c\u53f8 Invex Therapeutics (ASX: IXC) \u5df2\u83b7\u51c6\u5728\u6fb3\u5927\u5229\u4e9a\u5f00\u59cb\u5176\u9488\u5bf9\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u7684 EVOLVE \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002","og_url":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-approved-start-presendin-phase-three-clinical-trial-australia\/","og_site_name":"smallcapsCN","article_published_time":"2022-07-04T01:07:33+00:00","article_modified_time":"2023-08-29T18:01:33+00:00","og_image":[{"width":640,"height":400,"url":"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/IND8471.jpg","type":"image\/jpeg"}],"author":"Small Caps","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Small Caps"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-approved-start-presendin-phase-three-clinical-trial-australia\/","url":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-approved-start-presendin-phase-three-clinical-trial-australia\/","name":"Invex Therapeutics \u83b7\u51c6\u5728\u6fb3\u5927\u5229\u4e9a\u542f\u52a8 Presendin \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c","isPartOf":{"@id":"https:\/\/smallcapscn.x5view.co\/#website"},"datePublished":"2022-07-04T01:07:33+00:00","dateModified":"2023-08-29T18:01:33+00:00","author":{"@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74"},"description":"\u4e34\u5e8a\u9636\u6bb5\u7684\u751f\u7269\u5236\u836f\u516c\u53f8 Invex Therapeutics (ASX: IXC) \u5df2\u83b7\u51c6\u5728\u6fb3\u5927\u5229\u4e9a\u5f00\u59cb\u5176\u9488\u5bf9\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u7684 EVOLVE \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002","breadcrumb":{"@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-approved-start-presendin-phase-three-clinical-trial-australia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/smallcapscn.x5view.co\/invex-therapeutics-approved-start-presendin-phase-three-clinical-trial-australia\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-approved-start-presendin-phase-three-clinical-trial-australia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/smallcapscn.x5view.co\/"},{"@type":"ListItem","position":2,"name":"Invex Therapeutics \u83b7\u51c6\u5728\u6fb3\u5927\u5229\u4e9a\u542f\u52a8 Presendin \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c"}]},{"@type":"WebSite","@id":"https:\/\/smallcapscn.x5view.co\/#website","url":"https:\/\/smallcapscn.x5view.co\/","name":"smallcapsCN","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74","name":"Small Caps","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g","caption":"Small Caps"},"description":"Small Caps provides coverage on Australian ASX listed small cap stocks across all sectors: mining, resources, energy, biotech, technology, juniors and IPOs.","url":"https:\/\/smallcapscn.x5view.co\/?author=5"}]}},"_links":{"self":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/5404"}],"collection":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5404"}],"version-history":[{"count":1,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/5404\/revisions"}],"predecessor-version":[{"id":15283,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/5404\/revisions\/15283"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/media\/18675"}],"wp:attachment":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5404"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5404"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5404"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}